To conclude, this research demonstrated through extensive in vitro and in vivo studies that USP36 is an oncogene in colon cancer through targeting c-Myc and uncovered CBF as a promising therapeutic agent for colon cancer. Here, MYC is linked to malignant colon neoplasm.